GB9900752D0
(en)
*
|
1999-01-15 |
1999-03-03 |
Angiogene Pharm Ltd |
Benzimidazole vascular damaging agents
|
SE9903544D0
(sv)
|
1999-10-01 |
1999-10-01 |
Astra Pharma Prod |
Novel compounds
|
GB2359551A
(en)
|
2000-02-23 |
2001-08-29 |
Astrazeneca Uk Ltd |
Pharmaceutically active pyrimidine derivatives
|
US20070021392A1
(en)
*
|
2000-03-31 |
2007-01-25 |
Davis Peter D |
Divided dose therapies with vascular damaging activity
|
CN1431999A
(zh)
*
|
2000-05-31 |
2003-07-23 |
阿斯特拉曾尼卡有限公司 |
具有血管损伤活性的吲哚衍生物
|
AR028948A1
(es)
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
Compuestos novedosos
|
SE0003828D0
(sv)
|
2000-10-20 |
2000-10-20 |
Astrazeneca Ab |
Novel compounds
|
WO2002044156A2
(en)
*
|
2000-11-29 |
2002-06-06 |
Glaxo Group Limited |
Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
|
WO2002067932A1
(en)
|
2001-01-11 |
2002-09-06 |
Board Of Regents, The University Of Texas System |
Antihelminthic drugs as a treatment for hyperproliferative diseases
|
JP2004529110A
(ja)
*
|
2001-03-06 |
2004-09-24 |
アストラゼネカ アクチボラグ |
脈管損傷活性を有するインドール誘導体
|
AU2002245927B2
(en)
*
|
2001-03-26 |
2005-11-17 |
Pitney Pharmaceuticals Pty Limited |
Method for treatment of cancer and compositions for use therein
|
EP1379242B1
(en)
*
|
2001-03-26 |
2012-08-15 |
Newsouth Innovations Pty Limited |
Method for treatment of cancer and compositions for use therein
|
EP1298125A1
(en)
|
2001-09-26 |
2003-04-02 |
Aventis Pharma S.A. |
Substituted benzimidazole compounds and their use for the treatment of cancer
|
AU2003202094B2
(en)
|
2002-02-01 |
2009-10-08 |
Astrazeneca Ab |
Quinazoline compounds
|
GB0217431D0
(en)
|
2002-07-27 |
2002-09-04 |
Astrazeneca Ab |
Novel compounds
|
ES2295685T3
(es)
|
2002-08-24 |
2008-04-16 |
Astrazeneca Ab |
Derivados de pirimidina como moduladores de la actividad del receptor de quimioquinas.
|
GB0221828D0
(en)
|
2002-09-20 |
2002-10-30 |
Astrazeneca Ab |
Novel compound
|
DE60328735D1
(de)
|
2002-12-24 |
2009-09-17 |
Astrazeneca Ab |
Chinazolinderivate
|
SE0301010D0
(sv)
|
2003-04-07 |
2003-04-07 |
Astrazeneca Ab |
Novel compounds
|
SE0301569D0
(sv)
|
2003-05-27 |
2003-05-27 |
Astrazeneca Ab |
Novel compounds
|
US7485643B2
(en)
|
2003-11-19 |
2009-02-03 |
Array Biopharma Inc. |
Bicyclic inhibitors of MEK and methods of use thereof
|
GB0328243D0
(en)
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Methods
|
KR20060127127A
(ko)
|
2004-01-05 |
2006-12-11 |
아스트라제네카 아베 |
Chk 1 억제제로서 티오펜 유도체
|
FR2868421B1
(fr)
|
2004-04-01 |
2008-08-01 |
Aventis Pharma Sa |
Nouveaux benzothiazoles et leur utilisation comme medicaments
|
SE0401657D0
(sv)
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0415320D0
(en)
|
2004-07-08 |
2004-08-11 |
Astrazeneca Ab |
Novel compounds
|
MX2007002240A
(es)
|
2004-08-28 |
2007-04-20 |
Astrazeneca Ab |
Derivados de pirimidinosulfonamida como moduladores del receptor quimiocina.
|
WO2006024092A1
(en)
|
2004-08-31 |
2006-03-09 |
Newsouth Innovations Pty Limited |
Vegf inhibition
|
CN101111248A
(zh)
*
|
2004-12-06 |
2008-01-23 |
新南部创新有限公司 |
癌症的治疗
|
RS52036B
(en)
|
2004-12-21 |
2012-04-30 |
Medimmune Limited |
ANGIOPOETIN-2 ANTIBODIES AND ITS USES
|
US7576090B2
(en)
|
2004-12-27 |
2009-08-18 |
4Sc Ag |
Benzazole analogues and uses thereof
|
EP1674466A1
(en)
*
|
2004-12-27 |
2006-06-28 |
4Sc Ag |
2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors
|
WO2006076376A1
(en)
*
|
2005-01-11 |
2006-07-20 |
Medicinova, Inc. |
Topical treatment of solid tumors and ocular neovascularization
|
NZ561145A
(en)
|
2005-02-04 |
2011-02-25 |
Astrazeneca Ab |
Pyrazolylaminopyridine derivatives useful as kinase inhibitors
|
PL2361905T3
(pl)
|
2005-05-18 |
2013-07-31 |
Array Biopharma Inc |
Heterocykliczne inhibitory MEK i sposoby ich stosowania
|
KR20080037655A
(ko)
|
2005-07-21 |
2008-04-30 |
아스트라제네카 아베 |
신규 피페리딘 유도체
|
TW200738634A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
JPWO2007034882A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
WO2007034917A1
(ja)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規なアデニン化合物
|
JPWO2007034881A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
US20090118263A1
(en)
|
2005-09-22 |
2009-05-07 |
Dainippon Sumitomo Pharma Co., Ltd. |
Novel Adenine Compound
|
EP1939200A4
(en)
|
2005-09-22 |
2010-06-16 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
FR2891273B1
(fr)
*
|
2005-09-27 |
2007-11-23 |
Aventis Pharma Sa |
NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
|
WO2007039736A1
(en)
|
2005-10-06 |
2007-04-12 |
Astrazeneca Ab |
Novel compounds
|
AU2006307657B2
(en)
|
2005-10-28 |
2010-10-28 |
Astrazeneca Ab |
4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
|
CA2632194C
(en)
|
2005-11-15 |
2012-01-03 |
Array Biopharma Inc. |
N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
|
TW200730512A
(en)
|
2005-12-12 |
2007-08-16 |
Astrazeneca Ab |
Novel compounds
|
PT1979001E
(pt)
|
2005-12-13 |
2012-07-13 |
Medimmune Ltd |
Proteínas de ligação específicas para factores de crescimento insulínicos e suas aplicações
|
EP1963259B1
(en)
|
2005-12-15 |
2012-02-15 |
AstraZeneca AB |
Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
CN102558021A
(zh)
|
2006-05-26 |
2012-07-11 |
阿斯利康(瑞典)有限公司 |
联芳基或芳基-杂芳基取代的吲哚类化合物
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
DE102006037478A1
(de)
|
2006-08-10 |
2008-02-14 |
Merck Patent Gmbh |
2-(Heterocyclylbenzyl)-pyridazinonderivate
|
ES2648388T3
(es)
*
|
2006-08-23 |
2018-01-02 |
Kudos Pharmaceuticals Limited |
Derivados de 2-metilmorfolin pirido-, pirazo- y pirimido-pirimidina como inhibidores de mTOR
|
TW200825084A
(en)
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
US20100113510A1
(en)
|
2006-12-19 |
2010-05-06 |
Rhonan Ford |
Quinuclidinol derivatives as muscarinic receptor antagonists
|
CL2008000191A1
(es)
|
2007-01-25 |
2008-08-22 |
Astrazeneca Ab |
Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
|
WO2008114819A1
(ja)
|
2007-03-20 |
2008-09-25 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規アデニン化合物
|
AR065784A1
(es)
|
2007-03-20 |
2009-07-01 |
Dainippon Sumitomo Pharma Co |
Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
DE102007025717A1
(de)
|
2007-06-01 |
2008-12-11 |
Merck Patent Gmbh |
Arylether-pyridazinonderivate
|
DE102007025718A1
(de)
|
2007-06-01 |
2008-12-04 |
Merck Patent Gmbh |
Pyridazinonderivate
|
CA2689514C
(en)
*
|
2007-06-05 |
2015-09-29 |
Takeda Pharmaceutical Company Limited |
Heterobicyclic compounds as kinase inhibitors
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
UA100983C2
(ru)
|
2007-07-05 |
2013-02-25 |
Астразенека Аб |
Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007038957A1
(de)
|
2007-08-17 |
2009-02-19 |
Merck Patent Gmbh |
6-Thioxo-pyridazinderivate
|
EP2181987B9
(en)
*
|
2007-08-23 |
2014-09-03 |
Takeda Pharmaceutical Company Limited |
2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer
|
DE102007041115A1
(de)
|
2007-08-30 |
2009-03-05 |
Merck Patent Gmbh |
Thiadiazinonderivate
|
WO2009044200A1
(en)
|
2007-10-04 |
2009-04-09 |
Astrazeneca Ab |
Steroidal [3, 2-c] pyrazole compounds, with glucocorticoid activity
|
PT2201012E
(pt)
|
2007-10-11 |
2014-09-04 |
Astrazeneca Ab |
Derivados de pirrolo[2,3-d]piridina como inibidores da proteína quinase b
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
MX343594B
(es)
|
2007-12-21 |
2016-11-11 |
Medimmune Ltd |
Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
SI2242759T1
(sl)
|
2008-02-06 |
2013-01-31 |
Astrazeneca Ab |
Spojine
|
US8735584B2
(en)
|
2008-02-28 |
2014-05-27 |
Merck Patent Gmbh |
Protein kinase inhibitors and use thereof
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
PL2297106T3
(pl)
|
2008-05-27 |
2015-01-30 |
Galderma Sa |
Pochodne fenoksypirydynyloamidu i ich zastosowania w leczeniu chorób, w których pośredniczy pde4
|
DE102008025750A1
(de)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
Dihydropyrazolderivate
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
DE102008029734A1
(de)
|
2008-06-23 |
2009-12-24 |
Merck Patent Gmbh |
Thiazolyl-piperidinderivate
|
UY31952A
(es)
|
2008-07-02 |
2010-01-29 |
Astrazeneca Ab |
5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
WO2010032060A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune Llc |
Antibodies directed to dll4 and uses thereof
|
DE102008052943A1
(de)
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
JO3101B1
(ar)
|
2008-12-02 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مشتقات بنزوثيازول كعوامل مضادة للسرطان
|
WO2010067102A1
(en)
|
2008-12-09 |
2010-06-17 |
Astrazeneca Ab |
Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
|
US7863325B2
(en)
|
2008-12-11 |
2011-01-04 |
Axcentua Pharmaceuticals Ab |
Crystalline genistein sodium salt dihydrate
|
WO2010068861A1
(en)
|
2008-12-11 |
2010-06-17 |
Axcentua Pharmaceutucals Ab |
Crystalline forms of genistein
|
US20100152197A1
(en)
|
2008-12-15 |
2010-06-17 |
Astrazeneca Ab |
(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
|
US9938268B2
(en)
|
2008-12-17 |
2018-04-10 |
Merck Patent Gmbh |
C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
US8853391B2
(en)
|
2008-12-18 |
2014-10-07 |
Merck Patent Gmbh |
Tricyclic azaindoles
|
TW201028410A
(en)
|
2008-12-22 |
2010-08-01 |
Astrazeneca Ab |
Chemical compounds 610
|
AU2009331528A1
(en)
|
2008-12-23 |
2011-08-11 |
Astrazeneca Ab |
Targeted binding agents directed to alpha5beta1 and uses thereof
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
DE102008062826A1
(de)
|
2008-12-23 |
2010-07-01 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102009003975A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
DE102009003954A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102009004061A1
(de)
|
2009-01-08 |
2010-07-15 |
Merck Patent Gmbh |
Pyridazinonderivate
|
WO2010089580A1
(en)
|
2009-02-06 |
2010-08-12 |
Astrazeneca Ab |
Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
|
WO2010092371A1
(en)
|
2009-02-10 |
2010-08-19 |
Astrazeneca Ab |
Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
|
GB0905127D0
(en)
|
2009-03-25 |
2009-05-06 |
Pharminox Ltd |
Novel prodrugs
|
UY32520A
(es)
|
2009-04-03 |
2010-10-29 |
Astrazeneca Ab |
Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
US20100317593A1
(en)
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
GB0913342D0
(en)
|
2009-07-31 |
2009-09-16 |
Astrazeneca Ab |
Compounds - 801
|
DE102009043260A1
(de)
|
2009-09-28 |
2011-04-28 |
Merck Patent Gmbh |
Pyridinyl-imidazolonderivate
|
WO2011039528A1
(en)
|
2009-10-02 |
2011-04-07 |
Astrazeneca Ab |
2-pyridone compounds used as inhibitors of neutrophil elastase
|
DE102009049679A1
(de)
|
2009-10-19 |
2011-04-21 |
Merck Patent Gmbh |
Pyrazolopyrimidinderivate
|
WO2011048409A1
(en)
|
2009-10-20 |
2011-04-28 |
Astrazeneca Ab |
Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
KR20120113709A
(ko)
|
2009-11-18 |
2012-10-15 |
아스트라제네카 아베 |
벤조이미다졸 화합물 및 그의 용도
|
RU2571204C3
(ru)
|
2009-11-24 |
2020-12-14 |
Медиммьюн Лимитед |
Специфические связывающие агенты против в7-н1
|
EP2507237A1
(en)
|
2009-12-03 |
2012-10-10 |
Dainippon Sumitomo Pharma Co., Ltd. |
Imidazoquinolines which act via toll - like receptors (tlr)
|
DE102009058280A1
(de)
|
2009-12-14 |
2011-06-16 |
Merck Patent Gmbh |
Thiazolderivate
|
CN102666489B
(zh)
|
2009-12-14 |
2014-07-23 |
默克专利有限公司 |
鞘氨醇激酶抑制剂
|
KR20120096076A
(ko)
|
2009-12-17 |
2012-08-29 |
메르크 파텐트 게엠베하 |
스핑고신 키나아제 저해제
|
WO2011085641A1
(en)
|
2010-01-15 |
2011-07-21 |
Suzhou Neupharma Co., Ltd. |
Certain chemical entities, compositions, and methods
|
KR20120120307A
(ko)
|
2010-01-19 |
2012-11-01 |
아스트라제네카 아베 |
피라진 유도체
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
WO2011114148A1
(en)
|
2010-03-17 |
2011-09-22 |
Astrazeneca Ab |
4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
|
US20130059916A1
(en)
|
2010-05-26 |
2013-03-07 |
Stephane Rocchi |
Biguanide compounds and its use for treating cancer
|
WO2011154677A1
(en)
|
2010-06-09 |
2011-12-15 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
GB201009801D0
(en)
|
2010-06-11 |
2010-07-21 |
Astrazeneca Ab |
Compounds 950
|
TW201219383A
(en)
|
2010-08-02 |
2012-05-16 |
Astrazeneca Ab |
Chemical compounds
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
DE102010034699A1
(de)
|
2010-08-18 |
2012-02-23 |
Merck Patent Gmbh |
Pyrimidinderivate
|
CN102656179B
(zh)
|
2010-08-28 |
2015-07-29 |
苏州润新生物科技有限公司 |
蟾蜍灵衍生物、其药物组合物及用途
|
GB201016442D0
(en)
|
2010-09-30 |
2010-11-17 |
Pharminox Ltd |
Novel acridine derivatives
|
DE102010048800A1
(de)
|
2010-10-20 |
2012-05-10 |
Merck Patent Gmbh |
Chinoxalinderivate
|
DE102010049595A1
(de)
|
2010-10-26 |
2012-04-26 |
Merck Patent Gmbh |
Chinazolinderivate
|
WO2012066336A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Benzylamine compounds as toll -like receptor 7 agonists
|
EP2640716A1
(en)
|
2010-11-19 |
2013-09-25 |
Dainippon Sumitomo Pharma Co., Ltd. |
Cyclic amide compounds and their use in the treatment of disease
|
WO2012067269A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Aminoalkoxyphenyl compounds and their use in the treatment of disease
|
WO2012066335A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Phenol compounds als toll -like receptor 7 agonists
|
CN103370317B
(zh)
|
2010-12-16 |
2015-10-07 |
阿斯利康(瑞典)有限公司 |
可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物
|
WO2012080730A1
(en)
|
2010-12-17 |
2012-06-21 |
Astrazeneca Ab |
Purine derivatives
|
BR112013015508B1
(pt)
|
2010-12-20 |
2022-04-05 |
Medimmune Limited |
Molécula de anticorpo para il-18 humana, domínio vh isolado e domínio vl isolado, composição, uso de uma molécula de anticorpo ou do domínio vh isolado e do domínio vl isolado, molécula de ácido nucleico isolada, célula hospedeira procariótica recombinante, método para produzir um anticorpo, e método in vitro para medir il-18 em uma amostra de um indivíduo
|
EP3453714B1
(en)
|
2011-02-02 |
2020-11-04 |
Suzhou Neupharma Co., Ltd |
Cardenolide and bufadienolide 3-carbonate and 3-carbamate derivatives for the treatment of cancer and compositions thereof
|
DK2675793T3
(da)
|
2011-02-17 |
2018-11-12 |
Cancer Therapeutics Crc Pty Ltd |
Fak-inhibitorer
|
CA2827172C
(en)
|
2011-02-17 |
2019-02-26 |
Cancer Therapeutics Crc Pty Limited |
Selective fak inhibitors
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
UY34013A
(es)
|
2011-04-13 |
2012-11-30 |
Astrazeneca Ab |
?compuestos de cromenona con actividad anti-tumoral?.
|
WO2012175991A1
(en)
|
2011-06-24 |
2012-12-27 |
Pharminox Limited |
Fused pentacyclic anti - proliferative compounds
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
PL3255043T3
(pl)
|
2011-07-12 |
2021-07-12 |
Astrazeneca Ab |
N-(6-(((2r,3s)-3,4-dihydroksybutan-2-yloksy)-2-(4-fluorobenzylotio)pirymidyn-4-ylo)-3- metyloazetydyno-1-sulfonamid jako modulator receptora chemokin
|
CN105254616B
(zh)
|
2011-07-27 |
2017-10-17 |
阿斯利康(瑞典)有限公司 |
取代的n‑(2‑甲氧基‑5‑硝基苯基)嘧啶‑2‑胺化合物及其盐
|
JP5651271B2
(ja)
*
|
2011-07-29 |
2015-01-07 |
メディシノヴァ, インコーポレイテッド. |
デニブリン二塩酸塩
|
DE102011111400A1
(de)
|
2011-08-23 |
2013-02-28 |
Merck Patent Gmbh |
Bicyclische heteroaromatische Verbindungen
|
CA2846574C
(en)
|
2011-08-26 |
2020-07-07 |
Neupharma, Inc. |
Quinoxaline sulfonamide derivates for use as kinase inhibitors
|
CN104080335B
(zh)
|
2011-09-01 |
2017-06-09 |
钱向平 |
某些化学实体、组合物及方法
|
WO2013040515A1
(en)
|
2011-09-14 |
2013-03-21 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
WO2013043935A1
(en)
|
2011-09-21 |
2013-03-28 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
WO2013045955A1
(en)
|
2011-09-29 |
2013-04-04 |
The University Of Liverpool |
Prevention and/or treatment of cancer and/or cancer metastasis
|
US9249111B2
(en)
|
2011-09-30 |
2016-02-02 |
Neupharma, Inc. |
Substituted quinoxalines as B-RAF kinase inhibitors
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
US9670180B2
(en)
|
2012-01-25 |
2017-06-06 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
US9409914B2
(en)
|
2012-01-28 |
2016-08-09 |
Merck Patent Gmbh |
Triazolo[4,5-d]pyrimidine derivatives
|
EA026611B1
(ru)
|
2012-02-09 |
2017-04-28 |
Мерк Патент Гмбх |
Производные тетрагидрохиназолинона в качестве ингибиторов tank и parp
|
US9045493B2
(en)
|
2012-02-09 |
2015-06-02 |
Merck Patent Gmbh |
Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives
|
ES2552518T3
(es)
|
2012-02-21 |
2015-11-30 |
Merck Patent Gmbh |
Derivados cíclicos de diaminopiridina como inhibidores de Syk
|
AU2013224421B2
(en)
|
2012-02-21 |
2017-03-02 |
Merck Patent Gmbh |
8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors
|
JP6097770B2
(ja)
|
2012-02-21 |
2017-03-15 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
フロピリジン誘導体
|
CA2866450C
(en)
|
2012-03-07 |
2020-02-18 |
Merck Patent Gmbh |
Triazolopyrazine derivatives
|
HUE030067T2
(en)
|
2012-03-28 |
2017-04-28 |
Merck Patent Gmbh |
Bicyclic pyrazinone derivatives
|
WO2013144532A1
(en)
|
2012-03-30 |
2013-10-03 |
Astrazeneca Ab |
3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
|
SG11201406238UA
(en)
|
2012-04-05 |
2014-10-30 |
Hoffmann La Roche |
Bispecific antibodies against human tweak and human il17 and uses thereof
|
WO2013165924A1
(en)
|
2012-04-29 |
2013-11-07 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
SG11201406997WA
(en)
|
2012-05-04 |
2014-11-27 |
Merck Patent Gmbh |
Pyrrolotriazinone derivatives
|
GB201211021D0
(en)
|
2012-06-21 |
2012-08-01 |
Cancer Rec Tech Ltd |
Pharmaceutically active compounds
|
EP2877485B1
(de)
|
2012-07-24 |
2018-03-14 |
Merck Patent GmbH |
Hydroxystatin-derivate zur behandlung von arthrose
|
CN104507942B
(zh)
|
2012-08-07 |
2017-03-22 |
默克专利股份公司 |
作为蛋白质激酶抑制剂的吡啶并嘧啶衍生物
|
RU2654216C2
(ru)
|
2012-08-08 |
2018-05-17 |
Мерк Патент Гмбх |
Производные (аза-)изохинолинона
|
AU2013302320A1
(en)
|
2012-08-17 |
2015-02-26 |
Cancer Therapeutics Crc Pty Limited |
VEGFR3 inhibitors
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
CN104812389B
(zh)
|
2012-09-24 |
2020-07-17 |
润新生物公司 |
某些化学实体、组合物及方法
|
BR112015006524A8
(pt)
|
2012-09-26 |
2019-08-20 |
Merck Patent Gmbh |
derivados de quinazolinona como inibidores de parp, seu processo de preparação, seu uso, medicamentos e conjunto (kit)
|
US10253107B2
(en)
|
2012-10-26 |
2019-04-09 |
The University Of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
JP6304776B2
(ja)
|
2012-11-05 |
2018-04-04 |
ジーエムディーエックス カンパニー プロプライエタリー リミテッド |
体細胞突然変異生成の原因を判定するための方法
|
EP2916838B1
(en)
|
2012-11-12 |
2019-03-13 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
ES2608355T3
(es)
|
2012-11-16 |
2017-04-10 |
Merck Patent Gmbh |
Derivados de 3-aminociclopentanocarboxamida.
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
CN105246888B
(zh)
|
2013-01-31 |
2017-09-05 |
尼奥迈德研究所 |
咪唑并吡啶化合物及其用途
|
WO2014127881A1
(de)
|
2013-02-25 |
2014-08-28 |
Merck Patent Gmbh |
2-amino-3,4-dihydrc-chinazolin derivate und ihre verwendung als cathepsin d inhibitoren
|
CA2903901A1
(en)
|
2013-03-05 |
2014-09-12 |
Merck Patent Gmbh |
9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
|
US9937137B2
(en)
|
2013-03-15 |
2018-04-10 |
Neurocentria, Inc. |
Magnesium compositions and uses thereof for cancers
|
WO2014144715A1
(en)
|
2013-03-15 |
2014-09-18 |
Memorial Sloan-Kettering Cancer Center |
Hsp90-targeted cardiac imaging and therapy
|
AR095443A1
(es)
|
2013-03-15 |
2015-10-14 |
Fundación Centro Nac De Investig Oncológicas Carlos Iii |
Heterociclos condensados con acción sobre atr
|
WO2014161570A1
(en)
|
2013-04-03 |
2014-10-09 |
Roche Glycart Ag |
Antibodies against human il17 and uses thereof
|
EP3004073A1
(en)
|
2013-06-07 |
2016-04-13 |
Université catholique de Louvain |
3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
|
SG11201510369WA
(en)
|
2013-06-25 |
2016-01-28 |
Univ Canberra |
Methods and compositions for modulating cancer stem cells
|
PL3035936T3
(pl)
|
2013-08-23 |
2019-08-30 |
Neupharma, Inc. |
Pewne jednostki chemiczne, kompozycje i sposoby
|
ES2851724T3
(es)
|
2013-09-18 |
2021-09-08 |
Epiaxis Therapeutics Pty Ltd |
Modulación de células madre
|
EP3052660A4
(en)
|
2013-10-01 |
2017-04-26 |
Queensland University Of Technology |
Kits and methods for diagnosis, screening, treatment and disease monitoring
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
WO2016029262A1
(en)
|
2014-08-25 |
2016-03-03 |
University Of Canberra |
Compositions for modulating cancer stem cells and uses therefor
|
CN107430126B
(zh)
|
2014-11-17 |
2019-12-06 |
昆士兰大学 |
食管腺癌和巴雷特食管的糖蛋白生物标志物及其用途
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
GB201501870D0
(en)
|
2015-02-04 |
2015-03-18 |
Cancer Rec Tech Ltd |
Autotaxin inhibitors
|
GB201502020D0
(en)
|
2015-02-06 |
2015-03-25 |
Cancer Rec Tech Ltd |
Autotaxin inhibitory compounds
|
EP3270694A4
(en)
|
2015-02-17 |
2018-09-05 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
USRE49850E1
(en)
|
2015-08-04 |
2024-02-27 |
Aucentra Therapeutics Pty Ltd |
N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
|
ES2873841T3
(es)
|
2015-08-26 |
2021-11-04 |
Gmdx Co Pty Ltd |
Métodos para detectar la recurrencia del cáncer
|
US11534451B2
(en)
|
2015-12-23 |
2022-12-27 |
Repluca Pty Ltd |
Nucleic acid oligomers and uses therefor
|
WO2017132728A1
(en)
|
2016-02-01 |
2017-08-10 |
University Of Canberra |
Proteinaceous compounds and uses therefor
|
DK3417294T3
(da)
|
2016-02-15 |
2022-02-21 |
Astrazeneca Ab |
Fremgangsmåder, som omfatter fast intermitterende dosering af cediranib
|
HUE060082T2
(hu)
|
2016-04-15 |
2023-01-28 |
Cancer Research Tech Ltd |
Heterociklusos vegyületek, mint RET kináz inhibitorok
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
KR102566924B1
(ko)
|
2016-07-29 |
2023-08-11 |
랩트 테라퓨틱스, 인크. |
케모카인 수용체 조절제 및 이의 용도
|
US10544106B2
(en)
|
2016-08-15 |
2020-01-28 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
US10919896B2
(en)
|
2016-09-22 |
2021-02-16 |
Cancer Research Technology Limited |
Preparation and uses of pyrimidinone derivatives
|
GB201617103D0
(en)
|
2016-10-07 |
2016-11-23 |
Cancer Research Technology Limited |
Compound
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
CA3045517A1
(en)
|
2016-12-05 |
2018-06-14 |
Apros Therapeutics, Inc. |
Pyrimidine compounds containing acidic groups
|
US11111245B2
(en)
|
2017-02-01 |
2021-09-07 |
Aucentra Therapeutics Pty Ltd |
Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
|
WO2018162625A1
(en)
|
2017-03-09 |
2018-09-13 |
Truly Translational Sweden Ab |
Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
|
GB201704325D0
(en)
|
2017-03-17 |
2017-05-03 |
Argonaut Therapeutics Ltd |
Compounds
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
CN108864079B
(zh)
|
2017-05-15 |
2021-04-09 |
深圳福沃药业有限公司 |
一种三嗪化合物及其药学上可接受的盐
|
EP3630291B9
(en)
|
2017-05-26 |
2024-05-29 |
Cancer Research Technology Limited |
Benzimidazolone derived inhibitors of bcl6
|
WO2018215798A1
(en)
|
2017-05-26 |
2018-11-29 |
Cancer Research Technology Limited |
2-quinolone derived inhibitors of bcl6
|
EP3630188B1
(en)
|
2017-05-31 |
2021-08-25 |
Amplio Pharma AB |
A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy
|
EP3648797A1
(en)
|
2017-07-05 |
2020-05-13 |
EPOS-Iasis Research and Development, Ltd |
Multifunctional conjugates
|
SI3661941T1
(sl)
|
2017-08-01 |
2023-04-28 |
Merck Patent Gmbh |
Tiazolopiridinski derivati kot antagonisti adenozinskih receptorjev
|
US11447505B1
(en)
|
2017-08-18 |
2022-09-20 |
Cancer Research Technology Limited |
Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
|
CN110944994B
(zh)
|
2017-08-21 |
2023-06-09 |
默克专利股份公司 |
作为腺苷受体拮抗剂的喹喔啉衍生物
|
CA3073333A1
(en)
|
2017-08-21 |
2019-02-28 |
Merck Patent Gmbh |
Bezimidazole derivatives as adenosine receptor antagonists
|
TWI702205B
(zh)
|
2017-10-06 |
2020-08-21 |
***聯邦商拜奧卡德聯合股份公司 |
表皮生長因子受體抑制劑
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
NL2019801B1
(en)
|
2017-10-25 |
2019-05-02 |
Univ Leiden |
Delivery vectors
|
KR20200104291A
(ko)
|
2017-11-06 |
2020-09-03 |
랩트 테라퓨틱스, 인크. |
항암제
|
DK3488868T3
(da)
|
2017-11-23 |
2023-11-27 |
Medac Ges Fuer Klinische Spezialpraeparate Mbh |
Farmaceutisk sammensætning til oral indgivelse, som indeholder sulfasalazin og/eller et organisk sulfasalazinsalt, fremstillingsfremgangsmåde samt anvendelse
|
EP3489222A1
(en)
|
2017-11-23 |
2019-05-29 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Sulfasalazine salts, production processes and uses
|
CN111757881B
(zh)
|
2018-01-15 |
2024-05-07 |
澳升医药公司 |
作为治疗剂的5-(嘧啶-4-基)噻唑-2-基脲衍生物
|
GB201801128D0
(en)
|
2018-01-24 |
2018-03-07 |
Univ Oxford Innovation Ltd |
Compounds
|
WO2019147862A1
(en)
|
2018-01-26 |
2019-08-01 |
Flx Bio, Inc. |
Chemokine receptor modulators and uses thereof
|
SG11202007492XA
(en)
|
2018-02-08 |
2020-09-29 |
Neupharma Inc |
Certain chemical entities, compositions, and methods
|
US11712435B2
(en)
|
2018-02-08 |
2023-08-01 |
The Johns Hopkins University |
Mebendazole prodrugs with enhanced solubility and oral bioavailability
|
WO2019175093A1
(en)
|
2018-03-12 |
2019-09-19 |
Astrazeneca Ab |
Method for treating lung cancer
|
SG11202009735QA
(en)
|
2018-04-13 |
2020-10-29 |
Cancer Research Tech Ltd |
Bcl6 inhibitors
|
CA3098562A1
(en)
|
2018-04-27 |
2019-10-31 |
Spruce Biosciences, Inc. |
Methods for treating testicular and ovarian adrenal rest tumors
|
US10857153B2
(en)
|
2018-06-04 |
2020-12-08 |
Apros Therapeutics, Inc. |
Pyrimidine compounds containing acidic groups
|
GB201809102D0
(en)
|
2018-06-04 |
2018-07-18 |
Univ Oxford Innovation Ltd |
Compounds
|
JP2021527051A
(ja)
|
2018-06-05 |
2021-10-11 |
ラプト・セラピューティクス・インコーポレイテッド |
ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
SI3853220T1
(sl)
|
2018-09-18 |
2024-04-30 |
F. Hoffmann-La Roche Ag |
Derivati kinazolina kot protitumorska sredstva
|
US11084829B2
(en)
|
2018-09-24 |
2021-08-10 |
Rapt Therapeutics, Inc. |
Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof
|
JP2022505872A
(ja)
|
2018-10-25 |
2022-01-14 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アデノシン受容体アンタゴニストとしての5-アザインダゾール誘導体
|
CA3117510A1
(en)
|
2018-10-25 |
2020-04-30 |
Merck Patent Gmbh |
5-azaindazole derivatives as adenosine receptor antagonists
|
GB201819126D0
(en)
|
2018-11-23 |
2019-01-09 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
AR117844A1
(es)
|
2019-01-22 |
2021-09-01 |
Merck Patent Gmbh |
Derivados de tiazolopiridina como antagonistas del receptor de adenosina
|
JP2022524759A
(ja)
|
2019-03-07 |
2022-05-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Shp2アンタゴニストとしてのカルボキサミド-ピリミジン誘導体
|
EP3946618A1
(en)
|
2019-04-05 |
2022-02-09 |
Storm Therapeutics Ltd |
Mettl3 inhibitory compounds
|
EP3952998A1
(en)
|
2019-04-08 |
2022-02-16 |
Merck Patent GmbH |
Pyrimidinone derivatives as shp2 antagonists
|
GB201905328D0
(en)
|
2019-04-15 |
2019-05-29 |
Azeria Therapeutics Ltd |
Inhibitor compounds
|
WO2020247054A1
(en)
|
2019-06-05 |
2020-12-10 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
GB201908885D0
(en)
|
2019-06-20 |
2019-08-07 |
Storm Therapeutics Ltd |
Therapeutic compounds
|
CA3152674A1
(en)
|
2019-08-31 |
2021-03-04 |
Etern Biopharma (Shanghai) Co., Ltd. |
Pyrazole derivatives for fgfr inhibitor and preparation method thereof
|
JP2022548690A
(ja)
|
2019-09-20 |
2022-11-21 |
アイディアヤ バイオサイエンシーズ,インコーポレイティド |
Parg阻害剤としての4-置換インドールおよびインダゾールスルホンアミド誘導体
|
GB201913988D0
(en)
|
2019-09-27 |
2019-11-13 |
Celleron Therapeutics Ltd |
Novel treatment
|
GB201914860D0
(en)
|
2019-10-14 |
2019-11-27 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
GB201915829D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915831D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
WO2021111124A1
(en)
|
2019-12-02 |
2021-06-10 |
Storm Therapeutics Limited |
Polyheterocyclic compounds as mettl3 inhibitors
|
GB202004960D0
(en)
|
2020-04-03 |
2020-05-20 |
Kinsenus Ltd |
Inhibitor compounds
|
GB202008201D0
(en)
|
2020-06-01 |
2020-07-15 |
Neophore Ltd |
Inhibitor compounds
|
GB202012482D0
(en)
|
2020-08-11 |
2020-09-23 |
Univ Of Huddersfield |
Novel compounds and therapeutic uses thereof
|
GB202012969D0
(en)
|
2020-08-19 |
2020-09-30 |
Univ Of Oxford |
Inhibitor compounds
|
WO2022074379A1
(en)
|
2020-10-06 |
2022-04-14 |
Storm Therapeutics Limited |
Mettl3 inhibitory compounds
|
US20240101589A1
(en)
|
2020-10-08 |
2024-03-28 |
Strom Therapeutics Limited |
Inhibitors of mettl3
|
US12030888B2
(en)
|
2021-02-24 |
2024-07-09 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
GB202102895D0
(en)
|
2021-03-01 |
2021-04-14 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
IL308163A
(en)
|
2021-05-03 |
2024-01-01 |
Merck Patent Gmbh |
FC antigen-binding conjugate drug fragments targeting HER2
|
AU2022276958A1
(en)
|
2021-05-17 |
2023-12-07 |
Hk Inno.N Corporation |
Benzamide derivative, method for preparing same, and pharmaceutical composition for prevention or treatment of cancer containing same as active ingredient
|
JP2024521789A
(ja)
|
2021-05-25 |
2024-06-04 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
EGFRを標的にするFc抗原結合性フラグメント-薬物抱合体
|
GB202107907D0
(en)
|
2021-06-02 |
2021-07-14 |
Storm Therapeutics Ltd |
Combination therapies
|
GB202108383D0
(en)
|
2021-06-11 |
2021-07-28 |
Argonaut Therapeutics Ltd |
Compounds useful in the treatment or prevention of a prmt5-mediated disorder
|
GB202110373D0
(en)
|
2021-07-19 |
2021-09-01 |
Neophore Ltd |
Inhibitor compounds
|
WO2023057394A1
(en)
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
CA3225500A1
(en)
|
2021-10-04 |
2023-04-13 |
Ulrich Luecking |
Parg inhibitory compounds
|
GB202117224D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Inhibitor compounds
|
GB202117225D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Protac compounds
|
WO2023131690A1
(en)
|
2022-01-10 |
2023-07-13 |
Merck Patent Gmbh |
Substituted heterocycles as hset inhibitors
|
GB202202006D0
(en)
|
2022-02-15 |
2022-03-30 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Anti-cancer treatment
|
GB202202199D0
(en)
|
2022-02-18 |
2022-04-06 |
Cancer Research Tech Ltd |
Compounds
|
WO2023175185A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
WO2023175184A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
GB202204935D0
(en)
|
2022-04-04 |
2022-05-18 |
Cambridge Entpr Ltd |
Nanoparticles
|
US20230322741A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
WO2023218201A1
(en)
|
2022-05-11 |
2023-11-16 |
Cancer Research Technology Limited |
Ikk inhibitors
|
GB202209404D0
(en)
|
2022-06-27 |
2022-08-10 |
Univ Of Sussex |
Compounds
|
WO2024030825A1
(en)
|
2022-08-01 |
2024-02-08 |
Neupharma, Inc |
Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
|
GB202213164D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213163D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213167D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213162D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Prodrugs
|
GB202213166D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2024074497A1
(en)
|
2022-10-03 |
2024-04-11 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
WO2024094962A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
|
WO2024094963A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
|
WO2024099898A1
(en)
|
2022-11-07 |
2024-05-16 |
Merck Patent Gmbh |
Substituted bi-and tricyclic hset inhibitors
|
GB202218672D0
(en)
|
2022-12-12 |
2023-01-25 |
Storm Therapeutics Ltd |
Inhibitory compounds
|